G.A.S. GESELLSCHAFT FUR ANALYTISCHESENSORSYSTEME M.B.H.

Their core work

GAS (Gesellschaft für Analytische Sensorsysteme) is a German SME that designs and builds analytical sensor instruments for chemical and biological detection. Their name says it plainly: they make systems that sense, measure, and identify substances — whether those are toxic agents in a disaster zone or bacterial and viral markers in a patient's breath. In TOXI-triage they contributed technology for rapid field identification of toxic chemicals in mass casualty events. In BreathSpec they helped develop a non-invasive breath analysis device capable of distinguishing bacterial from viral respiratory infections within minutes. Their core competency is translating complex chemical analysis — typically confined to a laboratory — into compact, deployable instruments that work in the field or at the point of care.

What they specialise in

How they've shifted over time

GAS's H2020 activity spans a single, compressed window (2015–2019), making long-term evolution difficult to chart with precision. Within that window, however, a clear directional shift is visible: their first project (TOXI-triage, 2015) sits squarely in the security and emergency response space, addressing toxic chemical threats. Their second project (BreathSpec, 2017) moves the same core sensing capability into healthcare, applying breath-based chemical analysis to infection diagnosis. This suggests a deliberate expansion from defence-adjacent markets toward medical diagnostics, using the same underlying analytical instrument expertise as the bridge. Whether that trajectory has continued beyond H2020 cannot be confirmed from available data.

GAS appears to be repositioning its sensor technology from security and CBRN applications toward medical diagnostics, a higher-volume market — making them an interesting partner for projects at the intersection of analytical chemistry and point-of-care health technology.

How they like to work

GAS participates exclusively as a consortium partner — they have never led an H2020 project — which is typical for a small specialist SME that provides specific technical hardware within a larger system. They joined mid-to-large consortia (TOXI-triage and BreathSpec each involved multiple academic, clinical, and industrial partners across several countries), suggesting they are comfortable operating in complex multi-partner environments where their sensor component is one piece of a broader solution. There is no evidence of repeated partnerships with the same organisations, indicating they bring their technology to new consortia rather than working within a fixed network.

GAS has worked with 24 unique consortium partners across 9 countries through just two projects, reflecting the large, pan-European consortia typical of H2020 Innovation Actions in the security and health sectors. Their geographic footprint is broadly European with no visible regional concentration.

What sets them apart

GAS occupies a narrow but commercially valuable niche: analytical sensing instruments that work fast, outside the lab, and in high-stakes environments. Very few SMEs combine CBRN emergency-response experience with medical breath diagnostics — both demanding the same underlying capability of miniaturised, accurate chemical analysis under pressure. For a consortium needing a hardware partner that can bridge security sensing and health diagnostics, GAS is a rare fit.

Highlights from their portfolio

• BreathSpec
  The largest EC grant GAS received (EUR 507,150) and the clearest demonstration of their pivot toward medical instrumentation — a non-invasive breath analyser for infection triage with obvious commercial potential beyond the project.
• TOXI-triage
  Their earliest H2020 project placed GAS inside a large security-pillar Innovation Action on CBRN mass-casualty response, establishing their credibility in high-stakes field detection.